Study compares cancer drug cost, benefit

June 6, 2017 by Anne Craig
Credit: CC0 Public Domain

Queen's University researcher Christopher Booth reveals the price of new cancer therapies is not associated with treatment effectiveness.

A new study from Queen's University professor Christopher Booth has revealed the pricing of appears to have no relationship to their effectiveness.

Through the review it was revealed that the most expensive drugs were not the most beneficial.

"Most members of the public (and many patients) may not understand that when they read about a new 'breakthrough cancer therapy' in the media it usually does not cure cancer but extends survival by a few weeks or perhaps a few months," says Dr. Booth (Oncology). "Given that these drugs are very expensive and have important side effects, these small improvements may not lead to real improvements in the overall health and well-being of our patients or society as a whole."

Using frameworks developed by the American Society of Clinical Oncology (ASCO) and the European Society of Medical Oncology (ESMO), Dr. Booth and his team studied all randomized controlled trials of new cancer drugs in non-small cell lung cancer, breast cancer, colorectal cancer and pancreatic cancer over a four-year period.

The study found that there was no relationship between the price of a cancer and the extent to which it improves patient survival and quality of life. The authors concluded that to deliver optimal cancer care in a sustainable health system will require oncologists and policy makers to reconcile the disconnect between drug cost and clinical benefit.

"Our data does not suggest the use of these agents is inappropriate. These treatments have been established based on well-conducted clinical trials," explains Dr. Booth. "Our concern is that the very small magnitude of benefit associated with many new treatments may not be fully appreciated by the public and by some patients."

Dr. Booth advocates moving towards a value-based system where treatments and interventions that have a greater benefit for patients and society receive more resources than treatments that offer little benefit. He says one model that is being considered is value-based pricing where cancer drugs that offer the largest benefit are sold at a higher price than drugs with negligible benefit.

"In our current system the price of a new cancer drug has no relationship to its benefit but is largely driven by the maximum price the market will bear," says Dr. Booth. "A value-based pricing system would encourage companies and researchers to focus on developing more effective medicines by offering greater financial returns for those therapies with substantial benefit and smaller financial returns for treatments with negligible benefits. If you think about it, this relationship between quality and cost is what drives most economic transactions and it has always seemed strange to me that it does not apply to new medicines.

The study was published in The Lancet Oncology.

Explore further: New drugs, higher costs offer little survival benefit in advanced lung cancer

More information: Joseph C Del Paggio et al. Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks, The Lancet Oncology (2017). DOI: 10.1016/S1470-2045(17)30415-1

Related Stories

New drugs, higher costs offer little survival benefit in advanced lung cancer

January 5, 2017
According to a University of Colorado Cancer Center study published this week in the Journal of Clinical Oncology, a decade that saw the development of new therapies for non-small cell lung cancer resulted in little survival ...

England's Cancer Drugs Fund 'failed to deliver meaningful value to patients and society'

April 27, 2017
Analysis of the drugs that were approved for use by the NHS Cancer Drugs Fund (CDF) in England has shown that the fund was not good value for patients and society and may have resulted in patients suffering unnecessarily ...

Researchers develop framework for value-based pricing of cancer drugs

August 27, 2015
At a time when cancer drug prices are rising rapidly, an innovative new study provides the framework for establishing value-based pricing for all new oncology drugs entering the marketplace. Using a highly sophisticated economic ...

What price for a year of life? Cancer specialists offer contradictory advice

April 20, 2012
Cancer doctors prescribe medicines with little consideration of the cost, meaning they don't demand any more benefit (in months of survival) from a very expensive drug than from a less expensive one, a new research report ...

Drug combination shows benefit in RAS-driven cancers

April 3, 2017
Cancers driven by the RAS oncogene are aggressive and difficult to treat, and thus far precision drugs haven't been able to target the mutant RAS gene successfully.

Expensive new cancer drugs have little effect on survival of many cancers

November 9, 2016
Despite considerable investment and innovation, new cancer drugs approved in the past 10 years may have little effect on survival in adults with cancer, raising a number of concerns, argues an expert in The BMJ today.

Recommended for you

Soy, cruciferous vegetables associated with fewer common breast cancer treatment side effects

December 11, 2017
Consuming soy foods (such as soy milk, tofu and edamame) and cruciferous vegetables (such as cabbages, kale, collard greens, bok choy, Brussels sprouts, and broccoli) may be associated with a reduction in common side effects ...

CAR T, immunotherapy bring new hope for multiple myeloma patients

December 11, 2017
Two investigational immunotherapy approaches, including chimeric antigen receptor (CAR) T cell therapy, have shown encouraging results in the treatment of multiple myeloma patients who had relapsed and were resistant to other ...

Tracking how multiple myeloma evolves by sequencing DNA in the blood

December 10, 2017
Although people with multiple myeloma usually respond well to treatment, the blood cancer generally keeps coming back. Following genetic changes in how the disease evolves over time will help to understand the disease and, ...

Landmark CAR-T cancer study published

December 10, 2017
Loyola University Medical Center is the only Chicago center that participated in the pivotal clinical trial of a groundbreaking cancer treatment that genetically engineers a patient's immune system to attack cancer cells.

Study finds emojis promising tool for tracking cancer patients' quality of life

December 10, 2017
In findings presented to the American Society of Hematology, Mayo Clinic researchers found that using emojis instead of traditional emotional scales were helpful in assessing patients' physical, emotional and overall quality ...

Study explores use of checkpoint inhibitors after relapse from donor stem cell transplant

December 10, 2017
Immunotherapy agents known as checkpoint inhibitors have shown considerable promise in patients with hematologic cancers who relapse after a transplant with donor stem cells. Preliminary results from the first clinical trial ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.